AHA: Avoidance of Aspirin Noninferior With LVAD in Advanced Heart Failure
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 16, 2023 -- Avoidance of aspirin as part of an antithrombotic regimen that includes a vitamin K agonist (VKA) is noninferior to an aspirin-containing regimen for patients with advanced heart failure receiving support from a fully magnetically levitated left ventricular assist device (LVAD), according to a study published online Nov. 11 in the Journal of the American Medical Association. The research was published to coincide with the American Heart Association Scientific Sessions 2023, held from Nov. 11 to 13 in Philadelphia.
Mandeep R. Mehra, M.B.B.S., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined whether excluding aspirin as part of the antithrombotic regimen with a fully magnetically levitated LVAD is safe and decreases bleeding in an international randomized study of aspirin versus placebo with VKA therapy. A total of 628 patients with advanced heart failure implanted with a fully magnetically levitated LVAD were included in the study; the primary analysis population included 296 and 293 patients in the placebo and aspirin groups, respectively.
The researchers found that more patients were alive and free of hemocompatibility events at 12 months in the placebo group versus the aspirin group (74 versus 68 percent), demonstrating the noninferiority of placebo. A reduction in nonsurgical bleeding events was seen in association with aspirin avoidance (relative risk, 0.66), with no increase in stroke or other thromboembolic events; this finding was consistent across diverse subgroups.
"The benefits of aspirin avoidance are associated with a decrease in hospitalization rates and cost of care due to bleeding complications," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Abbott, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Gains in Heart Failure Mortality Have Been Erased
FRIDAY, April 26, 2024 -- Declines in heart failure-related mortality from 1999 to 2012 were entirely reversed from 2012 to 2021, according to a research letter published online...
Reports of Injuries, Deaths Prompt FDA to Recall Heart Failure Devices
WEDNESDAY, April 17, 2024 -- The HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories, are now under a strict U.S. Food and Drug...
American College of Cardiology, April 6 to 8
The annual meeting of the American College of Cardiology was held from April 6 to 8 in Atlanta and attracted more than 12,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.